Adicet Bio, Inc. business relationships
Companies named in Adicet Bio, Inc.’s 10-K filed 2026-03-12, and public companies whose annual reports name Adicet Bio, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 23 / 100 Top 2% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Adicet Bio, Inc.’s annual report 4
“We depend substantially on our license agreements with Regeneron, CRISPR and City of Hope.” SEC filing
“In addition to developing CARs and TCRs for use in novel immune-cell therapies as part of the collaboration, Regeneron will have the right to use these CARs and TCRs in our other antibody programs outside of the collaboration.” SEC filing
“...gic agreements and collaborations, including our License and Collaboration Agreement with Regeneron, our Antibody Discovery Agreement with Twist Bioscience Corporation, our License and Collaboration Agreement with CRISPR Therapeutics AG, and our Non-Exclusive License Agreement with the City of Hope.” SEC filing
“collaboration agreement with CRISPR Therapeutics AG (CRISPR), and our license agreement with the City of Hope, that we believe can provide us with additional capabilities beneficial to our business.” SEC filing
Companies whose annual reports name Adicet Bio, Inc. 1
“Some of our partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, Adicet Bio, Ono Pharmaceutical Ltd., Kyowa Kirin, Invetx, Inc., Astellas Pharma Inc. and Neogene Therapeutics, Inc.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.